We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

BECKMAN COULTER, INC.

Beckman Coulter develops, manufactures and markets laboratory systems, reagents, centrifugation, lab automation, elec... read more Featured Products: More products

Download Mobile App





Beckman Coulter's New Solutions Demonstrated at 2013 AACC Annual Meeting

By LabMedica International staff writers
Posted on 01 Aug 2013
Print article
Beckman Coulter (Brea, CA, USA) demonstrated its dedication to advancing and optimizing the lab at the 2013 American Association of Clinical Chemistry (AACC) and Clinical Lab Expo in Houston (TX, USA) from July 30–August 1, 2013.

The Beckman Coulter exhibition booth showcased the company’s latest products in total lab automation, scalable solutions, and small footprint systems, including the new Power Express automation solution which streamlines lab workflow and increases flexibility to ultimately decrease turnaround time. The Power Link, also demonstrated, offers labs the ability to combine an AU680 chemistry analyzer with a DxI immunoassay analyzer to form an entry level automated workcell.

Moreover, the latest addition of the IRIS Diagnostics (Chatsworth, CA, USA) urinalysis portfolio and presentations on the company’s newest troponin I assay, AccuTnI+3 on the Access 2 immunoassay system was demonstrated.

Attendees were given opportunities to view Beckman Coulter's newest cellular analysis systems, high-throughput chemistry analyzers, and clinical information solutions in a unique booth design that exhibits the company’s lab automation for the core, reference, and community hospital lab.

Visitors to Beckman Coulter’s booth have the opportunity to learn from industry experts how the company’s latest diagnostic innovations advance and optimize patient care and hear examples of how Beckman Coulter moves the lab forward by increasing efficiency, productivity, and uptime.

Related Links:
Beckman Coulter
Iris Diagnostics


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: Professor Nicole Strittmatter (left) and first author Wei Chen stand in front of the mass spectrometer with a tissue sample (Photo courtesy of Robert Reich/TUM)

Mass Spectrometry Detects Bacteria Without Time-Consuming Isolation and Multiplication

Speed and accuracy are essential when diagnosing diseases. Traditionally, diagnosing bacterial infections involves the labor-intensive process of isolating pathogens and cultivating bacterial cultures,... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.